Minerva Neurosciences Inc. (NASDAQ:NERV) stock has reached a new 52-week low, trading at $2.03, as investors show concern ...

StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a report published on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s ...

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 8.6% of Minerva Neurosciences shares are ...

Shares in Minerva Neurosciences have lost more than half their value after the FDA rejected its marketing application for roluperidone as a treatment for the negative symptoms of schizophrenia.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous ...

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...